Ethotoin

CHEMBL1095 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
204.2 g/mol
LogP
1.0
Phase
4

This hydantoin anticonvulsant stabilizes nerve cell membranes to reduce the spread of abnormal electrical activity that causes seizures. It is used to treat certain types of epilepsy when other medications are not suitable.

分子量

204.2200 g/mol

LogP

1.00

TPSA

49.40 Ų

Lipinski 五规则

符合

作用机制

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCN1C(=O)NC(c2ccccc2)C1=O

InChI

InChI=1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15)

Molecular Formula

C11H12N2O2

HBD / HBA

1 / 2

可旋转键数

2

重原子数

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

This hydantoin anticonvulsant stabilizes nerve cell membranes to reduce the spread of abnormal electrical activity that causes seizures. It is used to treat certain types of epilepsy when other medications are not suitable.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Ethotoin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1095. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3292. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.